Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
293.22
-2.74 (-0.93%)
Nov 28, 2025, 4:00 PM EST - Market closed
Penumbra Revenue
Penumbra had revenue of $354.69M in the quarter ending September 30, 2025, with 17.82% growth. This brings the company's revenue in the last twelve months to $1.33B, up 14.61% year-over-year. In the year 2024, Penumbra had annual revenue of $1.19B with 12.86% growth.
Revenue (ttm)
$1.33B
Revenue Growth
+14.61%
P/S Ratio
8.59
Revenue / Employee
$296,400
Employees
4,500
Market Cap
11.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 136.09M | 12.86% |
| Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
| Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
| Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
| Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PEN News
- 8 days ago - Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 22 days ago - Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Penumbra, Inc. Reports Third Quarter 2025 Financial Results - PRNewsWire
- 25 days ago - Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism - PRNewsWire
- 4 weeks ago - Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism - PRNewsWire
- 4 weeks ago - Penumbra, Inc. (PEN) Presents at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 - PRNewsWire
- 2 months ago - Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha